Gentian Diagnostics ASA (OSL:GENT)
Norway
· Delayed Price · Currency is NOK | Market Cap | 678.63M |
| Revenue (ttm) | 176.50M |
| Net Income (ttm) | 13.26M |
| Shares Out | 15.46M |
| EPS (ttm) | 0.86 |
| PE Ratio | 51.07 |
| Forward PE | 16.76 |
| Dividend | 0.60 (1.37%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 13,483 |
| Average Volume | 10,970 |
| Open | 42.60 |
| Previous Close | 43.90 |
| Day's Range | 42.60 - 43.50 |
| 52-Week Range | 36.10 - 65.80 |
| Beta | 0.32 |
| RSI | 57.08 |
| Earnings Date | May 6, 2026 |
About Gentian Diagnostics ASA
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne... [Read more]
Financial Performance
In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.
Financial StatementsNews
Gentian Diagnostics ASA Earnings Call Transcript: Q4 2025
Record sales and profitability were achieved in 2025, led by Cystatin C’s 32% growth and strong US expansion. A new exclusive partnership and high-sensitivity technology project were announced, while NT-proBNP assay development faced a setback.
Gentian Diagnostics ASA Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and EBITDA growth, led by U.S. expansion and Cystatin C adoption. Gross margin recovered, and R&D advanced NT-proBNP and other projects. Cautious outlook for China, but U.S. momentum expected to continue.
Gentian Diagnostics ASA Earnings Call Transcript: Q2 2025
Q2 sales rose 14% year-over-year to NOK 43.6 million, led by strong Cystatin C and U.S. growth. Gross margin dropped to 44% due to one-off production issues, but margins are expected to recover. NT-proBNP assay development remains on track for 2026 launch.
Gentian Diagnostics ASA Earnings Call Transcript: Q1 2025
Record Q1 sales and profitability driven by strong growth across all products and regions, with Cystatin C and other key assays performing exceptionally. Gross margin exceeded 60%, and the NT-proBNP assay is on track for a 2026 commercial launch.
Gentian Diagnostics ASA Earnings Call Transcript: Q4 2024
Record sales and profitability improvements in 2024, with strong growth in the U.S. and Europe, while China showed early signs of recovery. EFCAL turbo led product growth, and the board proposed the first-ever dividend. NT-proBNP launch remains on track for late 2025.
Gentian Diagnostics ASA Earnings Call Transcript: Q3 2024
Q3 2024 delivered strong EBITDA and improved gross margin, despite soft revenue growth due to lower China sales. fCAL turbo sales surged 76% year-over-year, and NT-proBNP assay advanced in clinical evaluation with a new patent granted.
Gentian Diagnostics ASA Earnings Call Transcript: Q2 2024
Q2 sales grew 12% year-over-year to NOK 38.3 million, with EBITDA more than tripling and gross margin rising to 57%. Strong product performance and partner-driven growth continue, though China sales face short-term uncertainty due to tendering changes.